IGF-I i inne czynniki wzrostu w nowotworach gruczołu sutkowego u psów i ludzi - ich rola w nowotworzeniu oraz znaczenie rokownicze

• Autorzy: Dolka I. , Malicka E. , Motyl T. , Sapierzynski R.

Warianty tytułu

EN

IGF and other growth factors in canine and human mammary tumors – their role in carcinogenesis and prognostic significance

• Języki publikacji: PL

Abstrakty

EN

The aim of this article is to summarize current data on the role of growth factors in the development of mammary tumors and their receptor expression as tumor markers. Particular attention is paid to IGF-I and IGF-IR in canine mammary tumors. The growth of a canine and human mammary cancer is regulated not only by sex steroid hormones but also by growth factors (GFs). Growth factors control such critical processes as the growth of the cell, differentiation, angiogenesis and apoptosis in a normal mammary gland. In malignancies these signaling pathways are often exploited to stimulate tumor growth and metastasis. In recent years there has been an increased understanding of aberrations in the insulin-like growth factor-I and its receptor (IGF-I, IGF-IR) responsible for or accompanying human and canine mammary carcinogenesis. IGF-IR demonstrates a tyrosine kinase activity and closely resembles the insulin receptor (IR) in structural as well as in signaling cascades. The binding of the ligands IGF-I or IGF-II to IGF-IR causes the phosphorylation of the IGF-IR tyrosine kinase rest located in the cytoplasmic portion of the β-subunit, then the Ras/ MAPK and PI-3K/Akt pathways associated with cell differentiation are activated and apoptosis is inhibited. IGF-IR is overexpressed in mammary tumor cells and has been implicated in tumor aggressiveness. IGF-IR expression contributes to cancer cell migration as well as cell-cell adhesion. The assessment of IGF-IR expression seems to be a significant indicator of prognosis. There are only a few studies on the role of IGF-I/IGF-IR in canine mammary neoplasms. Interestingly, the cross-talk between estrogens/ERα and IGF-I/IGF-IR has been demonstrated in breast cancer. Most in vitro studies demonstrate that estrogens and IGF-I have a synergistic effect on the proliferation of breast cancer cells. In the case of canine mammary tumors this potential relationship has not been thoroughly investigated, but it has been hypothesized that such a mechanism of cross-talk between sex hormones and the IGF-I pathway might promote carcinogenesis in an autocrine/paracrine manner. A further understanding of this mechanism could lead to the development of new therapeutic strategies in canine and human mammary neoplasms.

Słowa kluczowe

PL

angiogeneza; czynniki wzrostu; ekspresja receptorow; insulinopodobny czynnik wzrostu-I; nowotwory; nowotwory gruczolu sutkowego; onkogeneza; przerzuty nowotworowe; receptor IGF-IR; rozwoj

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2010
• Tom: 66
• Numer: 11
• Opis fizyczny: s.745-750,fot.,rys.,bibliogr.

Twórcy

autor

Dolka I.

• Katedra Patologii i Diagnostyki Weterynaryjnej, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego, ul.Nowoursynowska 159c, 02-776 Warszawa

autor

Malicka E.

autor

Motyl T.

autor

Sapierzynski R.

Bibliografia

• 1.Bonneterre J., Peyrat J. P., Beuscart R., Demaille A.: Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res. 1990, 50, 6931-6935.
• 2.Bontenbal M., Foekens J. A., Lamberts S. W., De Jong F. H., Putten W. L. van, Braun H. J., Burghouts J. T., Linden G. H. van der, Klijn J. G.: Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br. J. Cancer. 1998, 77, 115-122.
• 3.Bradley L. M., Gierthy J. F., Pentecost B. T.: Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line. J. Steroid Biochem. Mol. Biol. 2008, 109, 185-196.
• 4.Cock De H., Ducatelle R., Tilmant K., De Schepper J.: Possible role for insulin-like growth factor-I in the pathogenesis of cystic endometrial hyperplasia pyometra complex in the bitch. Theriogenology 2002, 57, 2271-2287.
• 5.Dickson R. B., Lippman M. E.: Growth factors in breast cancer. Endocr. Rev. 1995, 16, 559-589.
• 6.Dowsett M., Cooke T., Ellis I., Gullick W. J., Gusterson B., Mallon E., Walker R.: Assessment of HER-2 status in breast cancer: why, when and how? Eur. J. Cancer. 2000, 36, 170-176.
• 7.Gajewska M., Motyl T.: IGF-binding proteins mediate TGF-beta 1-induced apoptosis in bovine mammary epithelial BME-UV1 cells. Comp. Biochem. Physiol. C. 2004, 139, 65-75.
• 8.Gama A., Gärtner F., Alves A., Schmitt F.: Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Res. Vet. Sci. 2009, 87, 432-437.
• 9.Garderen E. van, De Wit M., Voorhout W. F., Rutteman G. R., Mol J. A., Nederbragt H., Misdorp W.: Expression of growth hormone in canine mammary tissue and mammary tumors. Evidence for a potential autocrine/paracrine stimulatory loop. Am. J. Pathol. 1997, 150, 1037-1047.
• 10.Hamelers I. H., Steenbergh P. H.: Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr. Relat. Cancer. 2003, 10, 331-345.
• 11.Henriksen K. L., Rasmussen B. B., Lykkesfeldt A. E., Møller S., Ejlertsen B., Mouridsen H. T.: An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009, 48, 522-531.
• 12.Kleinberg D. L., Ruan W.: IGF-I, GH, and sex steroid effects in normal mammary gland development. J. Mammary Gland Biol. Neoplasia 2008, 13, 353-360.
• 13.Koda M., Reszec J., Sulkowska M., Kanczuga-Koda L., Sulkowski S.: Expression of the Insulin-Like Growth Factor-I Receptor and proapoptotic Bax and Bak proteins in human colorectal cancer. Ann. N. Y. Acad. Sci. 2004, 1030, 377-383.
• 14.Koda M., Sulkowski S., Garofalo C., Kanczuga-Koda L., Sulkowska M., Surmacz E.: Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors alpha and beta. Horm. Metab. Res. 2003, 35, 794-801.
• 15.Kurimoto M., Fukuda I., Hizuka N., Takano K.: The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr. J. 2008, 55, 67-71.
• 16.Lee W. M., Kooistra H. S., Mol J. A., Dieleman S. J., Schaefers-Okkens A. C.: Ovariectomy during the luteal phase influences secretion of prolactin, growth hormone, and insulin-like growth factor-I in the bitch. Theriogenology 2006, 15, 484-490.
• 17.Mauro L., Salerno M., Morelli C., Boterberg T., Bracke M. E., Surmacz E.: Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J. Cell. Physiol. 2003, 194, 108-116.
• 18.Mol J. A., van Garderen E., Rutteman G. R., Rijnberk A.: New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. J. Steroid Biochem. Mol. Biol. 1996, 57, 67-71.
• 19.Oosterlaken-Dijksterhuis M. A., Kwant M. M., Slob A., Hellmén E., Mol J. A.: IGF-I and retinoic acid regulate the distribution pattern of IGFBPs synthesized by the canine mammary tumor cell line CMT-U335. Breast Cancer Res. Treat. 1999, 54, 11-23.
• 20.Ordás J., Millán M. Y., Espinosa de los Monteros A., Reymundo C., Martin De Las Mulas J.: Immunohistochemical expression of progesterone receptors, growth hormone and insulin growth factor-I in feline fibroadenomatous change. Res. Vet. Sci. 2004, 76, 227-233.
• 21.Queiroga F. L., Pérez-Alenza M. D., Silvan G., Peña L., Lopes C. S., Illera J. C.: Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17β-estradiol) in canine mammary tumours. J. Steroid Biochem. Mol. Biol. 2008, 110, 76-82.
• 22.Restucci B., Papparella S., Maiolino P., De Vico G.: Expression of Vascular Endothelial Growth Factor in canine mammary tumours. Vet. Pathol. 2002, 39, 488-493.
• 23.Rocha R. L., Hilsenbeck S. G., Jackson J. G., van den Berg C. L., Weng C., Lee A. V., Yee D.: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res. 1997, 3, 103-109.
• 24.Rungsipipat A., Tateyama S., Yamaguchi R., Uchida K., Miyoshi N., Hayashi T.: Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J. Vet. Med. Sci. 1999, 61, 27-32.
• 25.Selman P. J., Mol J. A., Rutteman G. R., Rijnberk A.: Progestin treatment in the dog. I. Effects on growth hormone, insulin-like growth factor I and glucose homeostasis. Eur. J. Endocrinol. 1994, 131, 413-421.
• 26.Shaw L. M.: Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the á6â4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol. Cell. Biol. 2001, 21, 5082-5093.
• 27.Simmen R. C., Simmen F. A., Hofig A., Farmer S. J., Bazer F. W.: Hormonal regulation of insulin-like growth factor gene expression in pig uterus. Endocrinology 1990, 127, 2166-2174.
• 28.Surmacz E.: Function of the IGF-I receptor in breast cancer. J. Mammary Gland Biol. Neoplasia 2000, 5, 95-105.
• 29.Turner B. C., Haffty B. G., Narayanan L., Yuan J., Havre P. A., Gumbs A. A., Kaplan L., Burgaud J. L., Carter D., Baserga R., Glazer P. M.: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997, 57, 3079-3083.
• 30.Yee D., Lee A. V.: Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J. Mammary Gland Biol. Neopl. 2000, 5, 107-115.